^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A*02:01

    i
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (NT-175-201) (NCT05877599)
    Phase 1
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2028
    Completion :
    08/01/2039
    TP53 • HLA-A
    |
    TP53 mutation • HLA-A*02:01
    |
    cyclophosphamide • fludarabine IV • NT-175
    H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas (CA209-8TX) (NCT02960230)
    Phase 1/2
    Sabine Mueller, MD, PhD
    Completed
    Last update posted :
    01/22/2025
    Initiation :
    11/18/2016
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    HLA-A
    |
    HLA-A*02:01 • H3.3K27M • HLA-A*02 positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hiltonol (poly-ICLC)
    Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (NCT06070012)
    Phase 2
    Diwakar Davar
    Not yet recruiting
    Last update posted :
    01/06/2025
    Initiation :
    01/31/2025
    Primary completion :
    11/30/2026
    Completion :
    11/30/2029
    LAG3 • CTLA4
    |
    HLA-A*02:01
    |
    Kimmtrak (tebentafusp-tebn)
    DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE) (NCT04106115)
    Phase 1/2
    University College, London
    Recruiting
    Last update posted :
    12/04/2024
    Initiation :
    03/25/2022
    Primary completion :
    05/31/2025
    Completion :
    05/31/2029
    PD-L1
    |
    HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • S-588210
    Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma (NCT02535078)
    Phase 1/2
    Immunocore Ltd
    Withdrawn
    Last update posted :
    07/24/2024
    Initiation :
    11/01/2015
    Primary completion :
    06/19/2023
    Completion :
    09/06/2023
    BRAF • HLA-A
    |
    BRAF mutation • HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Kimmtrak (tebentafusp-tebn)
    ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (NCT05601752)
    Phase 2
    Adaptimmune
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/26/2023
    Primary completion :
    08/12/2026
    Completion :
    08/12/2026
    HLA-A • BRCA • PARP1 • MAGEA4
    |
    HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
    |
    Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)
    Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma (NCT06066359)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/30/2023
    Primary completion :
    08/31/2026
    Completion :
    08/31/2028
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02
    |
    cyclophosphamide • fludarabine IV
    Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) (NCT03967223)
    Phase 2
    Adaptimmune
    Active, not recruiting
    Last update posted :
    04/25/2024
    Initiation :
    12/31/2019
    Primary completion :
    08/28/2024
    Completion :
    07/31/2026
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)
    Phase 1
    Fred Hutchinson Cancer Center
    Suspended
    Last update posted :
    03/21/2024
    Initiation :
    02/23/2018
    Primary completion :
    10/16/2027
    Completion :
    07/16/2028
    HLA-A • CD4
    |
    HLA-A*02:01
    |
    fludarabine IV • HA-1 T TCR T Cell Immunotherapy
    Phase II Study of TAEST16001 in Soft Tissue Sarcoma (NCT05549921)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    07/08/2022
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02
    |
    TAEST16001
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299)
    Phase 2
    GlaxoSmithKline
    Active, not recruiting
    Last update posted :
    10/16/2023
    Initiation :
    12/31/2019
    Primary completion :
    10/12/2022
    Completion :
    07/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    TEIPP Immunotherapy in Patients With NSCLC (NCT05898763)
    Phase 1/2
    Erasmus Medical Center
    Recruiting
    Last update posted :
    09/13/2023
    Initiation :
    09/29/2021
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    CD8
    |
    HLA-A*02:01
    |
    Keytruda (pembrolizumab)
    Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (NCT01176474)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    07/19/2023
    Initiation :
    08/13/2010
    Primary completion :
    08/01/2020
    Completion :
    01/06/2023
    CTAG1B
    |
    HLA-A*02:01
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 (NCT01176461)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    01/18/2023
    Initiation :
    08/04/2010
    Primary completion :
    12/12/2016
    Completion :
    12/12/2016
    CTAG1B
    |
    HLA-A*02:01
    |
    Opdivo (nivolumab)
    Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (IMA950-106) (NCT03665545)
    Phase 1/2
    University Hospital, Geneva
    Active, not recruiting
    Last update posted :
    12/26/2022
    Initiation :
    10/25/2018
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    PD-L1
    |
    HLA-A*02:01
    |
    Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950
    Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (NCT04878484)
    Phase 1
    Athenex, Inc.
    Withdrawn
    Last update posted :
    09/02/2022
    Initiation :
    08/11/2021
    Primary completion :
    10/01/2022
    Completion :
    12/01/2024
    CD8 • CTAG1B
    |
    HLA-A*02:01 • CTAG1B expression
    |
    TCRT-ESO-A2
    HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889)
    Phase 1
    Medigene AG
    Withdrawn
    Last update posted :
    10/08/2021
    Initiation :
    07/02/2020
    Primary completion :
    07/01/2023
    Completion :
    07/01/2025
    CD8 • HLA-A
    |
    HLA-A*02:01 • HLA-A*02 • HLA-A2 positive
    Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist (NCT00960752)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    08/13/2021
    Initiation :
    05/20/2010
    Primary completion :
    07/20/2020
    Completion :
    07/20/2020
    CD8 • CD4
    |
    HLA-A*02:01
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    02/04/2021
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    12/01/2021
    HLA-A • MSLN • CTAG1B
    |
    HLA-A*02:01 • MSLN positive • HLA-A positive
    |
    cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (NCT00090896)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    08/03/2020
    Initiation :
    04/01/2004
    Primary completion :
    07/01/2008
    Completion :
    10/01/2009
    HLA-A • CTLA4
    |
    HLA-A*02:01 • HLA-A positive
    |
    Imjudo (tremelimumab-actl)
    Vaccine Therapy in Treating Patients With Liver Cancer (NCT00022334)
    Phase 1/2
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    08/03/2020
    Initiation :
    01/01/2001
    Primary completion :
    12/01/2004
    Completion :
    10/01/2008
    AFP
    |
    HLA-A*02:01
    Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    12/11/2019
    Initiation :
    03/01/2018
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
    |
    HLA-A*02:01 • CD19 expression • HLA-A positive
    |
    cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (NCT02550535)
    Phase 1/2
    Cell Medica Ltd
    Completed
    Last update posted :
    10/02/2018
    Initiation :
    09/01/2015
    Primary completion :
    05/01/2018
    Completion :
    05/01/2018
    WT1
    |
    HLA-A*02:01
    |
    CMD-602
    WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (NCT01334060)
    Phase 2
    University Hospital Southampton NHS Foundation ...
    Completed
    Last update posted :
    09/07/2018
    Initiation :
    02/01/2011
    Primary completion :
    02/01/2013
    Completion :
    02/26/2013
    ABL1 • BCR • WT1
    |
    HLA-A*02:01
    |
    p.DOM-WT1-126 DNA vaccine
    Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome (NCT00270452)
    Phase 1
    National Heart, Lung, and Blood Institute (NHLBI)
    Completed
    Last update posted :
    07/02/2017
    Initiation :
    12/22/2005
    Primary completion :
    10/26/2007
    Completion :
    10/26/2007
    CSF2
    |
    HLA-A*02:01
    CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant (NCT01475058)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    02/15/2017
    Initiation :
    04/01/2012
    Primary completion :
    04/01/2014
    Completion :
    07/01/2014
    CD19 • HLA-B
    |
    HLA-A*02:01 • CD19 expression
    Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (NCT00923195)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/28/2015
    Initiation :
    12/01/2008
    Primary completion :
    08/01/2011
    Completion :
    08/01/2011
    IL2
    |
    HLA-A*02:01
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous